来那度胺
Tier B — Position earlyLenalidomide
Targets：CRBN、IKZF1、IKZF3、CSNK1A1、TNFα
Brand：Revimid (former Brand Name)、Leavdo、Zelvina、瑞复美
Indications (approved)：边缘带B细胞淋巴瘤、滤泡性淋巴瘤、成人T细胞白血病淋巴瘤、套细胞淋巴瘤、骨髓增生异常综合征、多发性骨髓瘤
Regional status
Synthetic routes & intermediates5 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LENA-001 | 59382-59-1Available | methyl 2-methyl-3-nitrobenzoate |
| LENA-002 | 128-08-5Available | 1-bromopyrrolidine-2,5-dione |
| LENA-003 | 98475-07-1Available | methyl 2-(bromomethyl)-3-nitrobenzoate |
| LENA-004 | 13726-85-7Available | (tert-butoxycarbonyl)-L-glutamine |
| LENA-005 | - | (R)-2-((tert-butoxycarbonyl)amino)-5-(4-nitro-1-oxoisoindolin-2-yl)-5-oxopentanoic acid |
| LENA-006 | - | (R)-2-amino-5-(4-nitro-1-oxoisoindolin-2-yl)-5-oxopentanoic acid |
| LENA-007 | 827026-45-9Available | 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENA-003 | 98475-07-1Available | methyl 2-(bromomethyl)-3-nitrobenzoate |
| LENA-008 | 366452-97-3Available | 4-nitroisoindolin-1-one |
| LENA-009 | 366452-98-4Available | 4-aminoisoindolin-1-one |
| LENA-010 | 760-94-1Available | dimethyl 2-bromopentanedioate |
| LENA-011 | 1198299-50-1Available | dimethyl 2-(4-amino-1-oxoisoindolin-2-yl)pentanedioate |
| LENA-012 | 110-94-1Available | glutaric acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENA-007 | 827026-45-9Available | 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| LENA-008 | 366452-97-3Available | 4-nitroisoindolin-1-one |
| LENA-010 | 760-94-1Available | dimethyl 2-bromopentanedioate |
| LENA-019 | 827026-43-7Available | dimethyl 2-(4-nitro-1-oxoisoindolin-2-yl)pentanedioate |
| LENA-020 | 1198299-54-5Available | methyl 5-amino-4-(4-nitro-1-oxoisoindolin-2-yl)-5-oxopentanoate |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENA-009 | 366452-98-4Available | 4-aminoisoindolin-1-one |
| LENA-021 | 50901-12-7Available | 3-(4-amino-1-oxoisoindolin-2-yl)dihydro-2H-pyran-2,6(3H)-dione |
| LENA-022 | 1198299-82-9Available | 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENA-013 | 52130-17-3Available | 3-amino-2-methylbenzoic acid |
| LENA-014 | 18583-89-6Available | methyl 3-amino-2-methylbenzoate |
| LENA-015 | 1465077-42-2Available | methyl 3-((tert-butoxycarbonyl)amino)-2-methylbenzoate |
| LENA-016 | 1537890-72-4Available | methyl 2-(bromomethyl)-3-((tert-butoxycarbonyl)amino)benzoate |
| LENA-017 | 24666-56-6Available | 3-aminopiperidine-2,6-dione hydrochloride |
| LENA-018 | 1537890-74-6Available | tert-butyl (2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)carbamate |
Frequently asked questions
What are the approved indications of Lenalidomide?
Approved indications include: 边缘带B细胞淋巴瘤, 滤泡性淋巴瘤, 成人T细胞白血病淋巴瘤, 套细胞淋巴瘤, 骨髓增生异常综合征, 多发性骨髓瘤.
When does the Lenalidomide patent expire?
No public expiry year is available for Lenalidomide yet; this page updates once verified.
How many synthesis routes are recorded for Lenalidomide?
5 synthesis routes are recorded; the shortest is 2 steps with 9.0 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Lenalidomide intermediates?
20 intermediate CAS of Lenalidomide are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Lenalidomide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24